menu
    • menu

    Company profile for Exelixis

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, caboz...
    Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tell the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ExelixisUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    210 East Grand Avenue
    Telephone
    Telephone
    650 837 8194, (650) 837-7000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    --
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Exelixis To Webcast Fireside Chats At November Investor
    Exelixis To Webcast Fireside Chats At November Investor

    06 Nov 2025

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20251106310715/en/Exelixis-to-Webcast-Fireside-Chats-as-Part-of-Upcoming-Investor-Conferences-in-November

    BUSINESS WIRE
    06 Nov 2025
    Share Share
    Exelixis Unveils Q3 2025 Financials & Corporate updates
    Exelixis Unveils Q3 2025 Financials & Corporate updates

    04 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251103969820/en/Exelixis-Announces-Third-Quarter-2025-Financial-Results-and-Provides-Corporate-Update

    BUSINESSWIRE
    04 Nov 2025
    Share Share
    Exelixis To Report Q3 2025 Financial Results On November 4
    Exelixis To Report Q3 2025 Financial Results On November 4

    21 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251021199733/en/Exelixis-to-Release-Third-Quarter-2025-Financial-Results-on-Tuesday-November-4-2025

    BUSINESSWIRE
    21 Oct 2025
    Share Share
    Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer
    Exelixis Kinase Blocker Sets Survival Bar In Colorectal Cancer

    21 Oct 2025

    // PRESS RELEASE

    https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-detailed-results-phase-3-stellar-303-pivotal

    PRESS RELEASE
    21 Oct 2025
    Share Share
    ESMO: Exelixis' TKI Reduces Risk Of Death By 20%
    ESMO: Exelixis' TKI Reduces Risk Of Death By 20%

    20 Oct 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/esmo-exelixis-franchise-molecule-reduces-risk-crc-death-20-compared-stivarga

    FIERCE BIOTECH
    20 Oct 2025
    Share Share
    Exelixis Ph3 Data on Zanzalintinib Published in Lancet
    Exelixis Ph3 Data on Zanzalintinib Published in Lancet

    20 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251015179453/en/Exelixis-Announces-Detailed-Results-from-Phase-3-STELLAR-303-Pivotal-Trial-Evaluating-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-in-Metastatic-Colorectal-Cancer-Presented-at-ESMO-2025-and-Published-in-The-Lancet

    BUSINESSWIRE
    20 Oct 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search